News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
412,512 Results
Type
Article (18739)
Company Profile (49)
Press Release (393723)
Multimedia
Podcasts (59)
Webinars (7)
Section
Business (118706)
Career Advice (1279)
Deals (24550)
Drug Delivery (65)
Drug Development (50379)
Employer Resources (84)
FDA (9436)
Job Trends (8901)
News (206057)
Policy (18793)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Standard (1)
Academia (1332)
Accelerated approval (20)
Adcomms (9)
Allergies (95)
Alliances (26316)
ALS (104)
Alzheimer's disease (987)
Antibody-drug conjugate (ADC) (184)
Approvals (9711)
Artificial intelligence (299)
Autoimmune disease (94)
Automation (25)
Bankruptcy (225)
Best Places to Work (7750)
BIOSECURE Act (8)
Biosimilars (122)
Biotechnology (39)
Bladder cancer (114)
Brain cancer (38)
Breast cancer (409)
Cancer (3150)
Cardiovascular disease (265)
Career advice (1088)
Career pathing (14)
CAR-T (174)
CDC (23)
Celiac Disease (1)
Cell therapy (479)
Cervical cancer (21)
Clinical research (44277)
Collaboration (984)
Company closure (1)
Compensation (1082)
Complete response letters (38)
COVID-19 (1463)
CRISPR (43)
C-suite (587)
Cystic fibrosis (95)
Data (4510)
Decentralized trials (1)
Denatured (38)
Depression (93)
Diabetes (329)
Diagnostics (4059)
Digital health (26)
Diversity (7)
Diversity, equity & inclusion (24)
Drug discovery (141)
Drug pricing (81)
Drug shortages (16)
Duchenne muscular dystrophy (167)
Earnings (57064)
Editorial (37)
Employer branding (11)
Employer resources (84)
Events (56214)
Executive appointments (715)
FDA (11668)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (8)
Frontotemporal dementia (14)
Funding (790)
Gene editing (102)
Generative AI (24)
Gene therapy (356)
GLP-1 (543)
Government (2030)
Grass and pollen (5)
Guidances (358)
Healthcare (11202)
HIV (37)
Huntington's disease (26)
IgA nephropathy (56)
Immunology and inflammation (133)
Immuno-oncology (34)
Indications (80)
Infectious disease (1623)
Inflammatory bowel disease (133)
Inflation Reduction Act (7)
Influenza (71)
Intellectual property (214)
Interviews (235)
IPO (12586)
IRA (27)
Job creations (1447)
Job search strategy (888)
JPM (27)
Kidney cancer (11)
Labor market (39)
Layoffs (191)
Leadership (26)
Legal (4694)
Liver cancer (58)
Longevity (7)
Lung cancer (420)
Lymphoma (250)
Machine learning (27)
Management (28)
Manufacturing (487)
MASH (123)
Medical device (8798)
Medtech (8839)
Mergers & acquisitions (12904)
Metabolic disorders (777)
Multiple sclerosis (118)
NASH (10)
Neurodegenerative disease (169)
Neuropsychiatric disorders (50)
Neuroscience (1764)
NextGen: Class of 2026 (3328)
Non-profit (1976)
Now hiring (8)
Obesity (318)
Opinion (186)
Ovarian cancer (106)
Pain (131)
Pancreatic cancer (174)
Parkinson's disease (167)
Partnered (20)
Patents (412)
Patient recruitment (317)
Peanut (33)
People (35914)
Pharmaceutical (20)
Pharmacy benefit managers (13)
Phase 1 (13299)
Phase 2 (19805)
Phase 3 (15180)
Pipeline (4062)
Policy (141)
Postmarket research (1220)
Preclinical (5315)
Press Release (27)
Prostate cancer (161)
Psychedelics (22)
Radiopharmaceuticals (201)
Rare diseases (524)
Real estate (2676)
Recruiting (43)
Regulatory (14943)
Reports (26)
Research institute (1177)
Resumes & cover letters (212)
Rett syndrome (24)
RNA editing (6)
RSV (51)
Schizophrenia (106)
Series A (130)
Series B (80)
Service/supplier (4)
Sickle cell disease (48)
Special edition (8)
Spinal muscular atrophy (89)
Sponsored (27)
Startups (1494)
State (2)
Stomach cancer (6)
Supply chain (67)
Tariffs (31)
The Weekly (21)
Vaccines (584)
Venture capital (45)
Weight loss (178)
Women's health (61)
Worklife (9)
Date
Today (13)
Last 7 days (369)
Last 30 days (1369)
Last 365 days (20932)
2026 (1935)
2025 (21163)
2024 (24273)
2023 (27655)
2022 (35121)
2021 (38048)
2020 (35472)
2019 (26991)
2018 (20207)
2017 (20197)
2016 (17922)
2015 (21562)
2014 (15491)
2013 (11834)
2012 (12831)
2011 (13621)
2010 (12302)
Location
Africa (396)
Alabama (62)
Alaska (4)
Arizona (136)
Arkansas (6)
Asia (24101)
Australia (3761)
California (7622)
Canada (2521)
China (718)
Colorado (376)
Connecticut (342)
Delaware (208)
Europe (53756)
Florida (1278)
Georgia (253)
Hawaii (1)
Idaho (30)
Illinois (554)
India (37)
Indiana (334)
Iowa (10)
Japan (317)
Kansas (90)
Kentucky (18)
Louisiana (15)
Maine (57)
Maryland (933)
Massachusetts (5207)
Michigan (222)
Minnesota (326)
Mississippi (2)
Missouri (77)
Montana (24)
Nebraska (16)
Nevada (98)
New Hampshire (55)
New Jersey (2153)
New Mexico (14)
New York (2209)
North Carolina (932)
North Dakota (3)
Northern California (3757)
Ohio (210)
Oklahoma (8)
Oregon (12)
Pennsylvania (1535)
Puerto Rico (21)
Rhode Island (24)
South America (657)
South Carolina (53)
Southern California (3033)
Tennessee (108)
Texas (1353)
United States (27243)
Utah (228)
Vermont (1)
Virginia (173)
Washington D.C. (43)
Washington State (650)
West Virginia (2)
Wisconsin (55)
Wyoming (1)
412,512 Results for "den mat holdings".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Calluna Pharma Announces the Appointment of Gijs van den Brink, MD, PhD, as Independent Director
December 16, 2025
·
2 min read
Press Releases
Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors
April 10, 2025
·
4 min read
Gene editing
FDA Lifts One of Two Clinical Holds on Intellia’s ATTR Gene Editing Program
After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs for hereditary transthyretin amyloidosis.
January 27, 2026
·
2 min read
·
Dan Samorodnitsky
Press Releases
IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer
September 9, 2025
·
6 min read
ADCs
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC
The FDA initially placed the Phase III IDeate-Lung02 study on hold due to a “higher than expected” number of deaths in patients treated with ifinatamab deruxtecan.
January 13, 2026
·
3 min read
·
Tristan Manalac
Pharm Country
In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
Matinas BioPharma Holdings, Inc. announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, demonstrated efficacy compared with placebo in treating the pulmonary mucormycosis fungal infections Rhizopus delemar and M. circinelloides f. jenssenii in immunosuppressed mice.
April 30, 2024
·
6 min read
Press Releases
IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer
September 4, 2025
·
4 min read
Pharm Country
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal platform delivery technology, announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, will be featured in a fireside chat with David S. Perlin, PhD, a recognized expert in antifungals.
June 13, 2024
·
6 min read
Press Releases
Cellbxhealth PLC Announces Holding(s) in Company
December 23, 2025
·
2 min read
Business
Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer
Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies, announced the appointment of Erik van den Berg as Chief Executive Officer.
November 16, 2023
·
3 min read
1 of 41,252
Next
